Borrelia C6 ELISA, Serum

Borrelia burgdorferi C6 ELISA

Serum

The use of the recombinant outer surface protein A (rOspA) vaccine (LYMErix; GlaxoSmithKline) confounds Lyme antibody testing as most methods detect OspA antibodies. A method that does not detect OspA antibodies is required for patients who might have received an OspA-based vaccine.
Source: Marques, A. R., Martin, D. S., & Philipp, M. T. (2002). Evaluation of the C6 Peptide Enzyme-Linked Immunosorbent Assay for Individuals Vaccinated with the Recombinant OspA Vaccine.Journal of Clinical Microbiology,40(7), 2591-2593. http://doi.org/10.1128/JCM.40.7.2591-2593.2002
This Borrelia C6-peptide ELISA utilizes such a method and can be used to diagnose Lyme disease in patients who have received the OspA vaccine. The assay is based on a peptide (C6) that reproduces the sequence of the invariable region 6 (IR6) of the VlsE (Vmp-like sequence, expressed) lipoprotein. It has been reported to be a sensitive and specific test for the serologic diagnosis of Lyme disease.